Edgar Filing: NEVRO CORP - Form 4

NEVRO CORP Form 4											
December 03, 2	015										
FORM 4	4		CECU						OMB APPROVAL		
	Washington, D.C. 20549							N OMB Number:	3235-0287		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. STATEMENT OF Filed pursuant to S Section 17(a) of the P				SECUI 16(a) of th Itility Hol	Estimated burden hou response	Estimated average burden hours per response 0.5					
<i>See</i> Instruction 1(b).		30(h)	of the I	nvestmen	t Compai	ny Act of 1	940				
(Print or Type Resp	oonses)										
1. Name and Address of Reporting Person <u>*</u> Galligan Andrew H			2. Issuer Name and Ticker or Trading Symbol NEVRO CORP [NVRO]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last)	(First) (I	Middle)	3. Date of Earliest Transaction				(en	ek an appread	()		
C/O NEVRO CORP., 1800 BRIDGE PARKWAY			(Month/Day/Year) 12/01/2015			Director 10% Owner X Officer (give title Other (specify below) below) Chief Financial Officer					
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person					
REDWOOD C							Form filed by Person	More than One R	eporting		
(City)	(State)	(Zip)	Tab	le I - Non-	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
	Transaction Date onth/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactic Code (Instr. 8) Code V	4. Securit mAcquired Disposed (Instr. 3, -	(A) or of (D)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Report	on a senarate line	for each cl	ass of sec	urities bene	ficially ow	ned directly	or indirectly				
Kenninger, Kepoli	on a separate fille				Perso inforr requi	ons who res nation con red to resp ays a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

8 E S

Edgar Filing: NEVRO CORP - Form 4

(Instr. 3)	Price of Derivative Security	(Mon	th/Day/Year)	(Instr.	8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)				(
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 63.23	12/01/2015		A		44,500		<u>(1)</u>	11/30/2025	Common Stock	44,500

Reporting Owners

Reporting Owner Name / Address	Relationships							
I State and the second	Director	10% Owner	Officer	Other				
Galligan Andrew H C/O NEVRO CORP. 1800 BRIDGE PARKWAY REDWOOD CITY, CA 94065			Chief Financial Officer					
Signatures								

/s/ Andrew 12/03/2015 Galligan **Signature of

Reporting Person

Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v). *
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- 1/48th of the shares subject to the option vest on each monthly anniversary measured from November 5, 2015 (the "Vesting
- (1) Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(